ReviewFrontiers in pharmacology2018
Role of Vonoprazan in
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Pooled it
- Evidence-based clinical practice guidelines for peptic ulcer disease 2020.Journal of gastroenterology · 2021Guideline
- Chemoprevention of gastric cancer development afterWorld journal of gastroenterology · 2020Pooled it
- Efficacy and safety of triple therapy with vonoprazan forWorld journal of gastroenterology · 2025Trial
- Trial
- Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy forFrontiers in cellular and infection microbiology · 2022Trial
- Simultaneous spectrophotometric eco-friendly analysis of triple-drug H.pylori regimen (Vonoprazan, Amoxicillin, Metronidazole) for quality control and in vitro dissolution testing.Scientific reports · 2026Article
- A Review on the Progress and Strategies ofGastroenterology research and practice · 2026Review
- Differences and trends in worldwide clinical guidelines forTranslational gastroenterology and hepatology · 2026Review
- Additional considerations on vonoprazan triple therapy forWorld journal of gastroenterology · 2025Article
- Vonoprazan and proton pump inhibitors: Which is superior forWorld journal of gastroenterology · 2025Article
- Article
- Antibiotic Resistance ofJournal of Korean medical science · 2024Review
- OptimizingGut and liver · 2023Review
- Article
- Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.Journal of clinical laboratory analysis · 2023Review
- Seven-day vonoprazan-based triple therapy as first-lineJGH open : an open access journal of gastroenterology and hepatology · 2023Article
- The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication ofFrontiers in pharmacology · 2023Article
- Research on antibiotic resistance inFrontiers in microbiology · 2023Article
- Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication ofFrontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complete eradication of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.